An expert’s word on the Microstent
170 implants later, this KOL can share her advice.
By Magda Rau, MD
As a diagnosis, DME often has company
Whatever the other condition, consider speaking to an expert in that field. Everyone benefits.
By Wendy Lyons Sunshine, Contributing
FDA rulings advance biosimilar drugs
Will the marketplace welcome “generic” Lucentis and others?
By Jerry Helzner, contributing editor
IN SO MANY WORDS
Genentech’s Anne Fung, MD
Leave no option unexplored
Seeking expert advice is a smart move before making a lease or purchase decision.
By Robert Stoneback, associate editor
Mastering IT matters, part 2
Get it running: EMR adoption and your IT managers
By Peter J. Polack, MD, FACS
My, how this snowball has rolled
Before 2000, no retinal therapies. How things changed.
By Jerry Helzner, contributing editor
OCTA: motion tells the tale
With angiography, increased speed allows an insightful look at the retina’s behavior.
By David Huang, MD, PhD
Quick Hits
By Robert Stoneback, associate editor
SPOTLIGHT ON TECHNOLOGY & TECHNIQUE
BIOM Ready’s motto: easy does it
By Robert Stoneback, associate editor
To treat DME, keep steroids close
Anti-VEGF therapies have their value, but some patients will be treated more effectively with a synthetic steroid.
By Stephen G. Schwartz, MD, MBA
Trying to keep pace with 80-year-olds ...
... and their AMD. The Big Three will have issues handling demand from our aging society.
By Evan N. Dunn, MD, and
Viewpoint
A breath of younger air
When shots and steroids won’t do
Centrally involved DME requires a special laser, at a special setting.
By Steven A. Agemy, MD, Jessica